{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:18:10Z","timestamp":1787987890889,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011933","name":"Chongqing Science and Technology Development Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011933","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pediatric lupus nephritis (pLN) is one of the most refractory secondary kidney diseases in childhood. The treat-to-target (T2T) strategy has become the standard treatment for systemic lupus erythematosus (SLE). This study reviewed clinical features, overall remission status, and factors affecting prognosis, to guide pLN management according to T2T strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective study studied 220 children diagnosed with LN from January 2012 to December 2018, with &gt; 6-month follow-up data on 173 and complete data on 137 patients. Primary outcome was treatment failure (deterioration or no response) at the latest follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The most common pLN manifestation was proteinuria (81.36%). Females presented more often with rash (P&lt;0.001) and alopecia (P=0.026) than males. Class IV LN (33.33%) was the most common grade on kidney biopsy. Median follow-up was 27.20 months (IQR, 15.78\u201344.45 months). One-, 3-, and 5-year cumulative overall survival rates were 93.5%, 87.8%, and 86.5%, respectively. The 5-year cumulative kidney survival rate was 97.1%. Regarding initial therapy, efficacy of corticosteroids combined with immunosuppressive agents was significantly better than corticosteroids alone (P=0.010). Factors with P&lt;0.05 in univariate analysis, including hypoalbuminemia, higher SCr at diagnosis, lower eGFR at diagnosis, anti-dsDNA positivity, heavy proteinuria, hypertension, nervous-system involvement, treatment non-compliance, and SLEDAI-2K score, were used for logistic regression analysis. Logistic regression analysis showed hypertension (OR=0.845, P=0.011), nervous-system involvement (OR=4.240, P=0.005), treatment non-compliance (OR=6.433, P=0.001), and lower estimated glomerular filtration rate at diagnosis (OR=1.020, P=0.021) affected prognosis. At end of follow-up, 34.31% achieved varying levels of remission, and 8.76% were in low disease activity state (LDAS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>pLN usually presented with proteinuria, and class IV LN was the dominant pathology. Hypertension, nervous-system involvement, treatment non-compliance, and lower eGFR at diagnosis were independent risk factors for poor prognosis of kidney outcomes. Compared with renal remission rate and cumulative overall survival rate, the proportion of targets achieved was not ideal, suggesting T2T strategy should be used to guide pLN management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-021-05164-y","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T07:10:03Z","timestamp":1628665803000},"page":"367-376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis"],"prefix":"10.1007","volume":"37","author":[{"given":"Shiyuan","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengci","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaofu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-3631","authenticated-orcid":false,"given":"Mo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"key":"5164_CR1","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nrrheum.2010.121","volume":"6","author":"S Kamphuis","year":"2010","unstructured":"Kamphuis S, Silverman E (2010) Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 6:538\u2013546. https:\/\/doi.org\/10.1038\/nrrheum.2010.121","journal-title":"Nat Rev Rheumatol"},{"key":"5164_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/1756-185X.12419","volume":"18","author":"A Aggarwal","year":"2014","unstructured":"Aggarwal A, Srivastava P (2014) Childhood onset systemic lupus erythematosus: how is it different from adult SLE? Int J Rheum Dis 18:182\u2013191","journal-title":"Int J Rheum Dis"},{"key":"5164_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10067-018-4259-z","volume":"38","author":"XY Wu","year":"2019","unstructured":"Wu XY, Yang M, Xie YS, Xiao WG, Lin J, Zhou B, Guan X, Luo CN, Che N, Liu XZ, Wang C, Teng JL, Cheng XB, Ye JN, Su YT, Shi H, Yin YF, Liu MR, Sun Y, Hu QY, Zhou ZC, Chi HH, Liu Y, Zhang X, Chen JW, Zhang MJ, Zhao DB, Yang CD, Wu LJ, Liu HL (2019) Causes of death in hospitalized patients with systemic lupus erythematosus: a 10-year multicenter nationwide Chinese cohort. Clin Rheumatol 38:107\u2013115. https:\/\/doi.org\/10.1007\/s10067-018-4259-z","journal-title":"Clin Rheumatol"},{"key":"5164_CR4","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","volume":"73","author":"R van Vollenhoven","year":"2014","unstructured":"van Vollenhoven R, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, Aringer M, Bootsma H, Boumpas D, Bruce IN, Cervera R, Clarke A, Costedoat-Chalumeau N, Czirjak L, Derksen R, Dorner T, Gordon C, Graninger W, Houssiau F, Inanc M, Jacobsen S, Jayne D, Jedryka-Goral A, Levitsky A, Levy R, Mariette X, Morand E, Navarra S, Neumann I, Rahman A, Rovensky J, Smolen J, Vasconcelos C, Voskuyl A, Voss A, Zakharova H, Zoma A, Schneider M (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73:958\u2013967. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205139","journal-title":"Ann Rheum Dis"},{"key":"5164_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/rheumatology\/kew377","volume":"56","author":"ASMW Tsang","year":"2017","unstructured":"Tsang ASMW, Bultink IE, Heslinga M, Voskuyl AE (2017) Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology (Oxford) 56:121\u2013128. https:\/\/doi.org\/10.1093\/rheumatology\/kew377","journal-title":"Rheumatology (Oxford)"},{"key":"5164_CR6","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/art.40571","volume":"70","author":"M Petri","year":"2018","unstructured":"Petri M, Magder LS (2018) Comparison of remission and lupus low disease activity state in damage prevention in a united states systemic lupus erythematosus cohort. Arthritis Rheum 70:1790\u20131795. https:\/\/doi.org\/10.1002\/art.40571","journal-title":"Arthritis Rheum"},{"key":"5164_CR7","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai A, Alarcon G, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677\u20132686. https:\/\/doi.org\/10.1002\/art.34473","journal-title":"Arthritis Rheum"},{"key":"5164_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3760\/cma.j.issn.0578-1310.2018.02.003","volume":"56","author":"Subspecialty Group of Renal Diseases, the Society of Pediatrics, Chinese Medical Association","year":"2018","unstructured":"Subspecialty Group of Renal Diseases, the Society of Pediatrics, Chinese Medical Association (2018) Evidence-based guideline on diagnosis and treatment of lupus nephritis (2016). Zhonghua Er Ke Za Zhi 56:88\u201394. https:\/\/doi.org\/10.3760\/cma.j.issn.0578-1310.2018.02.003","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"5164_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"G Schwartz","year":"2009","unstructured":"Schwartz G, Munoz A, Schneider M, Mak R, Kaskel F, Warady B, Furth S (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637. https:\/\/doi.org\/10.1681\/ASN.2008030287","journal-title":"J Am Soc Nephrol"},{"key":"5164_CR10","first-page":"288","volume":"29","author":"D Gladman","year":"2002","unstructured":"Gladman D, Iba\u00f1ez D, Urowitz M (2002) Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 29:288\u2013291","journal-title":"J Rheumatol"},{"key":"5164_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","volume":"65","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D\u2019Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65:521\u2013530. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00443.x","journal-title":"Kidney Int"},{"key":"5164_CR12","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/0002-9343(83)90338-8","volume":"75","author":"H Austin","year":"1983","unstructured":"Austin H, Muenz L, Joyce K, Antonovych T, Kullick M, Klippel J, Decker J, Balow J (1983) Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 75:382\u2013391. https:\/\/doi.org\/10.1016\/0002-9343(83)90338-8","journal-title":"Am J Med"},{"key":"5164_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/art.21625","volume":"54","author":"Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria","year":"2006","unstructured":"Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria (2006) The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 54:421\u2013432. https:\/\/doi.org\/10.1002\/art.21625","journal-title":"Arthritis Rheum"},{"key":"5164_CR14","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono CS, Chen SL, Jin O, Morton S, Hoi A, Huq M, Nikpour M, Morand EF (2016) Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 75:1615\u20131621. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207726","journal-title":"Ann Rheum Dis"},{"key":"5164_CR15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"BH Hahn","year":"2012","unstructured":"Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, FitzGerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi S-I, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM (2012) American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 64:797\u2013808. https:\/\/doi.org\/10.1002\/acr.21664","journal-title":"Arthritis Care Res"},{"key":"5164_CR16","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1177\/0961203312443421","volume":"21","author":"V Sato","year":"2012","unstructured":"Sato V, Marques I, Goldenstein PT, Carmo L, Jorge L, Titan S, Barros R, Woronik V (2012) Lupus nephritis is more severe in children and adolescents than in older adults. Lupus 21:978\u2013983. https:\/\/doi.org\/10.1177\/0961203312443421","journal-title":"Lupus"},{"key":"5164_CR17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1177\/0961203315619031","volume":"25","author":"P Srivastava","year":"2016","unstructured":"Srivastava P, Abujam B, Misra R, Lawrence A, Agarwal V, Aggarwal A (2016) Outcome of lupus nephritis in childhood onset SLE in North and Central India: single-centre experience over 25 years. Lupus 25:547\u2013557. https:\/\/doi.org\/10.1177\/0961203315619031","journal-title":"Lupus"},{"key":"5164_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/0961203319836712","volume":"28","author":"E Smith","year":"2019","unstructured":"Smith E, Al-Abadi E, Armon K, Bailey K, Ciurtin C, Davidson J, Gardner-Medwin J, Haslam K, Hawley D, Leahy A, Leone V, McErlane F, Mewar D, Modgil G, Moots R, Pilkington C, Ramanan A, Rangaraj S, Riley P, Sridhar A, Wilkinson N, Beresford MW, Hedrich CM (2019) Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus 28:613\u2013620. https:\/\/doi.org\/10.1177\/0961203319836712","journal-title":"Lupus"},{"key":"5164_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1177\/0961203317716317","volume":"27","author":"C Donnelly","year":"2018","unstructured":"Donnelly C, Cunningham N, Jones J, Ji L, Brunner H, Kashikar-Zuck S (2018) Fatigue and depression predict reduced health-related quality of life in childhood-onset lupus. Lupus 27:124\u2013133. https:\/\/doi.org\/10.1177\/0961203317716317","journal-title":"Lupus"},{"key":"5164_CR20","first-page":"879","volume":"37","author":"P Vachvanichsanong","year":"2019","unstructured":"Vachvanichsanong P, McNeil E, Dissaneewate P (2019) A 30-year retrospective study on causes of death in childhood-onset systemic lupus erythematosus in a tertiary care centre in Southern Thailand. Clin Exp Rheumatol 37:879\u2013884","journal-title":"Clin Exp Rheumatol"},{"key":"5164_CR21","doi-asserted-by":"publisher","first-page":"21032106","DOI":"10.1136\/annrheumdis-2015-208231","volume":"74","author":"R van Vollenhoven","year":"2015","unstructured":"van Vollenhoven R, Voskuyl A, Morand E, Aranow C (2015) Remission in SLE: closing in on the target. Ann Rheum Dis 74:21032106. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208231","journal-title":"Ann Rheum Dis"},{"key":"5164_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/annrheumdis-2017-211613","volume":"77","author":"M Zen","year":"2018","unstructured":"Zen M, Iaccarino L, Gatto M, Saccon F, Larosa M, Ghirardello A, Punzi L, Doria A (2018) Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 77:104\u2013110. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211613","journal-title":"Ann Rheum Dis"},{"key":"5164_CR23","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00467-017-3583-x","volume":"32","author":"B Basu","year":"2017","unstructured":"Basu B, Roy B, Babu BG (2017) Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol 32:1013\u20131021. https:\/\/doi.org\/10.1007\/s00467-017-3583-x","journal-title":"Pediatr Nephrol"},{"key":"5164_CR24","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","volume":"79","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, Calderon JE, Chasnyk VG, Ferrandiz MA, Keltsev V, Paz Gastanaga ME, Shishov M, Boteanu AL, Henrickson M, Bass D, Clark K, Hammer A, Ji BN, Nino A, Roth DA, Struemper H, Wang ML, Martini A, Lovell D, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) (2020) Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis 79:1340\u20131348. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217101","journal-title":"Ann Rheum Dis"},{"key":"5164_CR25","doi-asserted-by":"publisher","unstructured":"Smith EMD, Gorst SL, Al-Abadi E, Hawley DP, Leone V, Pilkington C, Ramanan AV, Rangaraj S, Sridhar A, Beresford MW, Young B (2021) \u201cIt is good to have a target in mind\u201d: qualitative views of patients and parents informing a treat to target clinical trial in JSLE. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keab173","DOI":"10.1093\/rheumatology\/keab173"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05164-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-021-05164-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05164-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T06:36:38Z","timestamp":1643956598000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-021-05164-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["5164"],"URL":"https:\/\/doi.org\/10.1007\/s00467-021-05164-y","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]},"assertion":[{"value":"29 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the ethical principles of the Helsinki Declaration of the World Medical Association and was approved by the ethics committee of the Children\u2019s Hospital of Chongqing Medical University (approval number: 93\/2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from legal guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The participants consented to the submission of the report for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}